In Karnataka, sudden deaths from KyasanurForest Disease raise concerns
Bengaluru: The number of
Kyasanur Forest Disease
(KFD) cases in Karnataka rose to 153, with four deaths reported so far this season. What concerns health authorities is not just the rise in infections, but the nature of the fatalities — all four patients initially showed signs of recovery before sudden deterioration in their conditions.
Medical investigations revealed that each case of death involved a different complication, leaving experts unable to establish a consistent clinical pattern. This unpredictability is making it harder for doctors to anticipate disease progression and adapt treatment protocols effectively.
"All the deaths occurred under close monitoring by govt-appointed doctors, and each case was investigated thoroughly," said Dr Ansar Ahmed, project director, Integrated Disease Surveillance Programme (IDSP). "These deaths were unexpected, and in many ways, unprecedented. That's why we believe there's an urgent need for more research and surveillance — both by ICMR and other govt institutions — as well as through collaboration with private research bodies and NGOs."
Dr Ahmed noted that KFD alone wasn't the direct cause in any of the fatalities. "I've personally gone through each case in detail. What we found is that every death had a different cause or underlying condition. In many instances, it was complications after KFD or pre-existing comorbidities that led to the fatal outcome. KFD, when combined with other health issues, can lead to unpredictable and rapid deterioration — and that's exactly what we've seen."
Chikmagalur and Shivamogga districts saw two deaths each of KFD patients. The most recent death occurred on April 17. An eight-year-old boy from Thirthahalli was under close monitoring by health officials for 12 days and was taken off the ventilator when his vitals seemed stable. However, he died the night his condition improved.
"Some of the recent deaths we've seen were entirely preventable," Harsh Gupta, principal secretary, health and family welfare department, said, adding: "In one case, the patient was on a ventilator with stable vitals, yet we lost them. It was deeply unfortunate. In other cases, multiple comorbidities made recovery extremely difficult. These were high-risk patients, and despite our best efforts, not all could be saved."
He added that the govt took proactive steps early in the season to strengthen KFD response systems. "We enhanced our alert and reporting mechanisms and ensured that no patient would be denied treatment due to financial constraints. The govt is covering the costs of care, including management of post-infection complications. This has helped us offer timely treatment and prevent more deaths."
However, officials admit that the sudden nature of recent fatalities exposed certain gaps in response and understanding of the disease. "While the situation looks better than last year in terms of overall caseload, the unexpected deaths have caught us off guard," Gupta said. "We're now coordinating with tertiary hospitals to conduct deeper clinical analysis. KFD doesn't present the same way every year — its symptoms, warning signs, and progression patterns seem to change. That means our treatment protocols must evolve too."
—
**BOX 2:
Districtwise cases since Jan 1
Chikamagalur: 83
Shivamogga: 65
Uttara Kannada: 6
Source: Health & family welfare dept
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Indian Express
19 hours ago
- Indian Express
‘Nicotine addiction hasn't disappeared, it has simply shape-shifted'
Smokeless tobacco is the number one problem in India and there is an urgent need to strengthen laws and regulations to address it effectively,' Dr Shalini Singh, director of the Indian Council of Medical Research-National Institute of Cancer Prevention (ICMR-NICPR) and the World Health Organisation-Framework Convention on Tobacco Control (WHO-FCTC) Global Knowledge Hub on Smokeless Tobacco told The Indian Express. On the sidelines of the World Conference of Tobacco Control under way at Dublin, Dr Singh observed that globally, cigarette smoking is on the decline — especially in high-income countries, where public health regulations have tightened and consumer behavior is shifting. 'But nicotine addiction hasn't disappeared; it has simply shape-shifted. The rise of electronic nicotine delivery systems (ENDS), synthetic nicotine pouches, and 'flavoured wellness' lozenges represents a quiet but aggressive reinvention of the nicotine business. These products are marketed as cleaner, safer, and even medicinal — often using the language of 'harm reduction'. While India has banned e-cigarettes, these new delivery systems pose a serious public health risk in countries with poor implementation of regulations,' Dr Singh said. India is already home to one of the largest populations of smokeless tobacco (SLT) and bidi users globally. According to the Global Adult Tobacco Survey (GATS) 2016–17, over 199 million Indians use SLT, 72 million smoke bidis, whereas only 37 million smoke cigarettes. Less than 4 per cent of tobacco users use any cessation pharmacotherapy, and over 70 per cent quit without formal help. 'This makes India an especially vulnerable target for the tobacco industry's new nicotine expansion strategy,' Dr Singh said. Harm reduction, when implemented as part of a comprehensive cessation strategy, has clinical value. But the tobacco industry has co-opted the term 'harm reduction' to further its own interests of reduced regulation and to expand its user base. While India banned e-cigarettes in 2019 under the Prohibition of Electronic Cigarettes Act, experts said the same industry has repackaged nicotine in non-combustible, e-cigarettes adjacent forms — such as synthetic nicotine pouches and gums — often marketed as herbal, Ayurvedic, or wellness products on Indian e-commerce platforms. 'This represents not only a strategic circumvention of the e-cigarette ban but also a continuation of the industry's practice of promoting products that protect profits while presenting a facade of supporting smoking cessation,' Dr Singh added. India permits over-the-counter (OTC) sale of 2 mg nicotine gums and lozenges, based on the assumption that easier accessibility would enhance tobacco cessation efforts. The 2 mg NRT formulation, particularly when used with behavioural counselling, can play a crucial role in reducing dependence on smoking tobacco. Global evidence is clear: NRTs are most effective when used with structured counselling and support, not when taken in isolation. Many low- and middle-income countries (LMICs), including India, have NRTs in OTC markets and require integration with comprehensive cessation services. In India, the effectiveness of OTC NRT is further undermined by systemic challenges: the very low cost of smokeless tobacco (SLT) products like gutkha, khaini, and bidis; the online sales of nicotine products frequently bypass age restrictions;and the economic burden of NRT — where one week's supply often costs more than a month's worth of SLT or bidi. Without counselling support and affordability measures, OTC NRT risks becoming another market commodity rather than a true cessation aid,' Dr Singh pointed out. Long-term use of nicotine — whether through vaping, pouches, or even unsupervised NRT — poses real risks. Yet, these products are increasingly available through online platforms in India, marketed with no warning labels, no age-gating, and no evidence-based cessation claims, Dr Singh cautioned. Urgent policy priorities include banning of flavoured and industry-manufactured non-combustible nicotine products, including gums and pouches not intended for supervised cessation. There is a need to tightly regulate OTC NRT, especially in flavours and formulations attractive to youth; regulate all online sales of nicotine products with mandatory age verification, licensing, and product labelling.
Time of India
21 hours ago
- Time of India
Indigenous rapid detection kit ready to detect Nipah virus with 100% accuracy: Director, ICMR-NIV
Pune: The Indian Council of Medical Research (ICMR) has developed a portable test kit for detecting Nipah virus cases with 100 per cent accuracy, which can provide results within 1- 2 hours. According to Dr Naveen Kumar, Director, ICMR-NIV, Pune, "Based on amplification of viral gene without the need for a specialised machine at the field level. It's 100 per cent sensitive and specific." This test can provide results in "1-2 hours". The Nipah virus is a Zoonotic virus that primarily spreads through fruit bats, and the virus has a 50% mortality rate, making it one of the most dangerous viral diseases. The cost of the test is 250 rupees, and the name of this kit is Loop-mediated isothermal amplification (LAMP) assay for rapid detection of Nipah virus. Meanwhile, Monoclonal antibody development is underway in collaboration with Zydus Health Sciences, Ahmedabad and Translational Health Sciences Technology Institute, Faridabad. The ICMR is also working on an indigenous vaccine for the Nipah virus. The National Institute of Virology (NIV) is the only lab in the country that cultures the Nipah virus. Nipah virus (NiV) is a zoonotic virus (it is transmitted from animals to humans) and can also be transmitted through contaminated food or directly between people. In infected people, it causes a range of illnesses from asymptomatic (subclinical) infection to acute respiratory illness and fatal encephalitis. The symptoms of the Nipah virus are fever, headaches, muscle pain, vomiting, sore throat, dizziness, altered consciousness, and Atypical pneumonia. Outbreaks of Nipah Virus Disease (NiVD) have been reported in Kerala, with the most recent one occurring in 2023 in the Kozhikode district.
Hans India
a day ago
- Hans India
Dire need to identify new drugs for patients with sickle cell disease: ICMR scientist
New Delhi: Identifying new drugs for patients with sickle cell disease is very important, said a senior scientist at the Indian Council of Medical Research (ICMR). Speaking to IANS, Dr. Manisha Madkaikar, Director of ICMR- Centre for Research Management and Control of Haemoglobinopathies (CRHCM) in Nagpur, shared that among many drugs only hydroxyurea therapy has so far been effective. Hydroxyurea has also been included in the National Health Mission's essential drugs list. However, the drug remains ineffective in many patients, prompting the need to find new and better treatments. 'We have known sickle cell disease for now so many decades. But it is only hydroxyurea therapy that has stood the test of time. Hydroxyurea significantly helps in improving the quality of life and complications in sickle cell disease patients,' Madkaikar said. 'However, there are some patients who do not respond to hydroxyurea therapy. Another drawback with hydroxyurea therapy is the patients have to take treatment lifelong, so that is the reason why a better drug is something which is desired, a better mode of therapy is desired,' she told IANS. The ICMR scientist said this even as the government, last week, announced an award of Rs 10 crore to develop a drug for the treatment of sickle cell disease. The tribal affairs ministry, in collaboration with the AIIMS-Delhi, will undertake a competition for the development of the drug. The selected proposal will be funded up to Rs 10 crore, said Union Minister of State for Tribal Affairs Durgadas Uikey at an event to mark World Sickle Cell Day in the national capital. Uikey also announced the institution of the Bhagwan Birsa Munda Prize for the development of a drug to treat the disease. Sickle cell disease is a genetic disorder mostly prevalent in districts with high tribal populations. About one in 86 births among STs have sickle cell disease which affects haemoglobin in red blood cells, resulting in morbidity and mortality. Madkaikar noted that there is a lot of research going on apart from bone marrow transplantation and gene therapy, which is available outside India but currently not available in India. 'We do not have any other drug which has shown promise like hydroxyurea therapy. So, there is a lot of scope or there is a lot of need for identifying such medicines which will transform the lives of patients with sickle cell disease,' the scientists said.
